139. Congenital cerebral hypomyelination Clinical trials / Disease details
Clinical trials : 10 / Drugs : 7 - (DrugBank : 2) / Drug target genes : 2 - Drug target pathways : 2
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02396459 (ClinicalTrials.gov) | December 7, 2020 | 7/3/2015 | Triac Trial II in MCT8 Deficiency Patients | Tiratricol Treatment of Children With Monocarboxylate Transporter 8 Deficiency: Triac Trial II | Allan-Herndon-Dudley Syndrome | Drug: Triac | Rare Thyroid Therapeutics International AB | Erasmus Medical Center | Recruiting | N/A | 30 Months | Male | 18 | Phase 2 | Netherlands |
| 2 | EUCTR2014-000178-20-CZ (EUCTR) | 04/02/2016 | 23/06/2015 | Therapy of MCT8 patients with the thyroid hormone analog Triac. | Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients | This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Téatrois (Tiratricol) Product Name: Téatrois | Erasmus Medical Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 40 | Phase 2 | Czech Republic;Belgium;Germany;Italy | ||
| 3 | EUCTR2014-000178-20-IT (EUCTR) | 01/02/2016 | 16/10/2015 | Therapy of MCT8 patients with the thyroid hormone analog Triac. | Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients | This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Téatrois (Tiratricol) Product Name: Téatrois | Erasmus Medical Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 40 | Phase 2 | Germany;Italy | ||
| 4 | EUCTR2014-000178-20-FR (EUCTR) | 14/01/2016 | 14/12/2015 | Therapy of MCT8 patients with the thyroid hormone analog Triac. | Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients | This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Téatrois (Tiratricol) Product Name: Téatrois | Erasmus Medical Centre | Centre Hospitalier de Toulouse | Not Recruiting | Female: no Male: yes | 40 | Phase 2 | France;Czech Republic;Canada;Belgium;Australia;South Africa;Germany;Italy | ||
| 5 | EUCTR2014-000178-20-BE (EUCTR) | 12/08/2015 | 22/06/2015 | Therapy of MCT8 patients with the thyroid hormone analog Triac. | Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients | This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Téatrois (Tiratricol) Product Name: Téatrois | Erasmus Medical Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 40 | Phase 2 | Canada;Belgium;Australia;Chile;South Africa;Germany;Italy | ||
| 6 | NCT02060474 (ClinicalTrials.gov) | October 2014 | 5/2/2014 | Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients | Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial. | Allan-Herndon-Dudley Syndrome | Drug: Triac | Erasmus Medical Center | ZonMw: The Netherlands Organisation for Health Research and Development | Completed | N/A | 99 Years | Male | 46 | Phase 2 | Netherlands |
| 7 | EUCTR2014-000178-20-DE (EUCTR) | 05/10/2015 | Therapy of MCT8 patients with the thyroid hormone analog Triac. | Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients | This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Téatrois (Tiratricol) Product Name: Téatrois INN or Proposed INN: Tiratricol | Erasmus Medical Centre | NULL | Not Recruiting | Female: no Male: yes | 40 | Phase 2 | France;Czech Republic;Canada;Belgium;Australia;Israel;South Africa;Germany;Italy |